Log in

NASDAQ:JYNTJoint Stock Price, Forecast & News

$14.50
+0.41 (+2.91 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$14.02
Now: $14.50
$14.67
50-Day Range
$13.77
MA: $14.96
$17.10
52-Week Range
$7.67
Now: $14.50
$21.80
Volume34,600 shs
Average Volume99,190 shs
Market Capitalization$202.13 million
P/E Ratio65.91
Dividend YieldN/A
Beta1.18
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of March 07, 2019, the company operated 450 clinics in the United States. The company was founded in 2010 and is headquartered in Scottsdale, Arizona.
Read More
Joint logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.78 out of 5 stars


Industry, Sector and Symbol

Industry Patent owners & lessors
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:JYNT
CUSIPN/A
Phone480-245-5960

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$48.45 million
Cash Flow$0.39 per share
Book Value$0.41 per share

Profitability

Net Income$3.32 million

Miscellaneous

Employees138
Market Cap$202.13 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive JYNT News and Ratings via Email

Sign-up to receive the latest news and ratings for JYNT and its competitors with MarketBeat's FREE daily newsletter.

Joint (NASDAQ:JYNT) Frequently Asked Questions

How has Joint's stock been impacted by COVID-19 (Coronavirus)?

Joint's stock was trading at $13.61 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, JYNT stock has increased by 6.5% and is now trading at $14.50. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Joint?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Joint in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Joint.

When is Joint's next earnings date?

Joint is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Joint.

How were Joint's earnings last quarter?

Joint Corp (NASDAQ:JYNT) issued its quarterly earnings data on Thursday, May, 7th. The company reported $0.06 EPS for the quarter, missing analysts' consensus estimates of $0.07 by $0.01. The firm had revenue of $13.64 million for the quarter, compared to analysts' expectations of $13.03 million. Joint had a return on equity of 66.44% and a net margin of 6.20%. View Joint's earnings history.

What price target have analysts set for JYNT?

5 brokers have issued twelve-month price objectives for Joint's stock. Their forecasts range from $20.00 to $30.00. On average, they expect Joint's share price to reach $23.40 in the next twelve months. This suggests a possible upside of 61.4% from the stock's current price. View analysts' price targets for Joint.

Has Joint been receiving favorable news coverage?

News stories about JYNT stock have been trending somewhat negative on Saturday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Joint earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Joint.

Are investors shorting Joint?

Joint saw a drop in short interest during the month of June. As of June 15th, there was short interest totaling 1,730,000 shares, a drop of 7.5% from the May 31st total of 1,870,000 shares. Based on an average daily volume of 161,900 shares, the short-interest ratio is currently 10.7 days. Currently, 13.2% of the shares of the company are short sold. View Joint's Current Options Chain.

Who are some of Joint's key competitors?

What other stocks do shareholders of Joint own?

Who are Joint's key executives?

Joint's management team includes the following people:
  • Mr. Peter D. Holt, CEO, Pres & Director (Age 60)
  • Jake Singleton, Chief Financial Officer (Age 37)
  • Mr. Jorge Armenteros, VP of Operations
  • Dr. James Edwards, Chief Chiropractic & Compliance Officer
  • Mr. Craig P. Colmar, Sec. (Age 66)

When did Joint IPO?

(JYNT) raised $20 million in an IPO on Tuesday, November 11th 2014. The company issued 3,000,000 shares at $6.50 per share. Roth Capital Partners and Feltl and Company served as the underwriters for the IPO and Sanders Morris Harris was co-manager.

What is Joint's stock symbol?

Joint trades on the NASDAQ under the ticker symbol "JYNT."

How do I buy shares of Joint?

Shares of JYNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Joint's stock price today?

One share of JYNT stock can currently be purchased for approximately $14.50.

How big of a company is Joint?

Joint has a market capitalization of $202.13 million and generates $48.45 million in revenue each year. The company earns $3.32 million in net income (profit) each year or $0.23 on an earnings per share basis. Joint employs 138 workers across the globe.

What is Joint's official website?

The official website for Joint is www.thejoint.com.

How can I contact Joint?

Joint's mailing address is 16767 N PERIMETER DRIVE SUITE 240, SCOTTSDALE AZ, 85260. The company can be reached via phone at 480-245-5960 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.